Fussey Jonathan Mark, Harterink Emilie, Gill Jaspreet, Child-Hymas Anne, McDermott Ann-Louise
Department of ENT Surgery, Birmingham Children's Hospital, UK.
Department of ENT Surgery, Birmingham Children's Hospital, UK.
Int J Pediatr Otorhinolaryngol. 2018 Aug;111:89-92. doi: 10.1016/j.ijporl.2018.05.033. Epub 2018 May 31.
Bone anchored hearing implants (BAHI) have been in use for over 30 years, and are commonly implanted in children for a range of indications. The Cochlear™ BIA300 system was launched in 2010 and used at The Birmingham Children's Hospital from 2011. Here we report the long-term outcomes of children implanted with the Cochlear™ BIA300 BAHI system in our centre.
A retrospective case note analysis was performed to identify outcomes in all children who underwent BIA300 implantation between 2011 and 2013.
52 children with a total of 78 implants were included. Mean age at implantation was 8.7 years. Mean follow-up was 43.5 months. Overall, 60 (77%) implants developed soft tissue complications requiring treatment. Forty-eight (62%) required topical treatment; 27 (35%) required systemic treatment; and 27 (35%) required surgical soft tissue revision under general anaesthesia.
The Cochlear™ BIA300 system appears to be associated with higher than expected rates of soft tissue reaction in children, with late as well as early soft tissue complications requiring both medical and surgical treatment.
骨锚式听力植入物(BAHI)已使用超过30年,常用于儿童多种适应症的治疗。科利耳™ BIA300系统于2010年推出,并于2011年开始在伯明翰儿童医院使用。在此,我们报告在我们中心接受科利耳™ BIA300 BAHI系统植入的儿童的长期结果。
进行回顾性病例记录分析,以确定2011年至2013年间所有接受BIA300植入的儿童的治疗结果。
纳入52名儿童,共植入78个植入物。植入时的平均年龄为8.7岁。平均随访时间为43.5个月。总体而言,60个(77%)植入物出现需要治疗的软组织并发症。48个(62%)需要局部治疗;27个(35%)需要全身治疗;27个(35%)需要在全身麻醉下进行手术软组织修复。
科利耳™ BIA300系统似乎与儿童中高于预期的软组织反应发生率相关,早期和晚期软组织并发症均需要药物和手术治疗。